Missing: Slate Bio's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Slate Bio's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Slate Bio News
Jan 28, 2021
Jan. 27, 2021 Slate Bio Inc., a startup developing an interleukin 2 fusion cytokine for the potential treatment of autoimmune and inflammatory diseases, has closed a $1.75 million seed financing led by Epidarex Capital. Financing for the company, a spinout of the University of Virginia, also came from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology's GAP Biolife Fund, VTC Seed Fund, Pharmadirections Inc., company management and others.
Slate Bio Web Traffic
Slate Bio Rank
Slate Bio Frequently Asked Questions (FAQ)
What is Slate Bio's latest funding round?
Slate Bio's latest funding round is Seed VC.
How much did Slate Bio raise?
Slate Bio raised a total of $1.75M.
Who are the investors of Slate Bio?
Investors of Slate Bio include Virginia Venture Partners, Epidarex Capital, University of Virginia Licensing & Ventures Group, VTC Seed Fund, PharmaDirections and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.